Continue to Site

Drug Discovery and Development

Gavreto is FDA-approved for RET-altered thyroid cancers

By |

GAVRETO Blueprint MedicinesFDA has indicated Gavreto (pralsetinib) from Blueprint Medicines to treat adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).

The drug was formerly known as BLU-667 and won FDA approval in September 2020.

CStone, which is developing the drug in China, received approval from that country’s regulatory authority, making it the first novel therapy for locally advanced or metastatic RET fusion-positive non-small cell lung cancer after platinum-based chemotherapy.

Filed Under: Oncology
Tagged With: , , , ,
 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected]

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development